Regardless, these results suggest that differences in the proportions of CD39−/+CD73+CD4+ T cells may contribute to an immune signature to help distinguish between HPV− and HPV+ HNSCC patients. This evidence concerns the gene CD4 and head and neck squamous cell carcinoma.